Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2006-08-01
2006-08-01
Saeed, Kamal A. (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C548S556000, C564S365000
Reexamination Certificate
active
07084165
ABSTRACT:
The present invention relates to compounds that are useful exhibit activity as serotonin, norepinephrine and dopamine reuptake inhibitors, and their pharmaceutically acceptable salts, and their use in the treatment of central nervous system and other disorders.
REFERENCES:
patent: 4161529 (1979-07-01), Beregi et al.
Elliot Mark Leonard
Howard, Jr. Harry Ralph
Schmidt Christopher Joseph
Seeger Thomas Francis
Joran A. David
Ling Lorraine B.
Pfizer Inc
Richardson Peter C..
LandOfFree
Monoamine reuptake inhibitors for treatment of CNS disorders does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Monoamine reuptake inhibitors for treatment of CNS disorders, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Monoamine reuptake inhibitors for treatment of CNS disorders will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3605433